XTX Topco Ltd Acquires 63,681 Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

Key Points

• XTX Topco Ltd increased its stake in Aurinia Pharmaceuticals Inc by 148.9% in the first quarter, acquiring an additional 63,681 shares to own a total of 106,435 shares valued at approximately $856,000.
• Analysts have raised their price targets for Aurinia Pharmaceuticals, with Royal Bank of Canada increasing it from $8.00 to $9.00 and HC Wainwright maintaining a buy rating with a target of $17.00.
• Aurinia Pharmaceuticals reported $70.01 million in revenue for the last quarter, exceeding expectations, although the company missed EPS estimates by a penny, reporting $0.16 against a target of $0.17.

XTX Topco Ltd lifted its holdings in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 148.9% in the first quarter, according to its most recent filing with the SEC. The firm owned 106,435 shares of the biotechnology company's stock after acquiring an additional 63,681 shares during the period. XTX Topco Ltd owned approximately 0.08% of Aurinia Pharmaceuticals worth $856,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of AUPH. GF Fund Management CO. LTD. bought a new position in Aurinia Pharmaceuticals during the fourth quarter worth about $27,000. Tower Research Capital LLC TRC lifted its position in Aurinia Pharmaceuticals by 368.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after buying an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC bought a new stake in Aurinia Pharmaceuticals during the 4th quarter worth about $31,000. GAMMA Investing LLC boosted its stake in shares of Aurinia Pharmaceuticals by 56.1% during the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock worth $39,000 after buying an additional 1,744 shares during the last quarter. Finally, Natixis acquired a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at approximately $49,000. Institutional investors and hedge funds own 36.83% of the company's stock.

Aurinia Pharmaceuticals Stock Down 0.7%

Shares of NASDAQ:AUPH traded down $0.09 during trading on Thursday, reaching $11.53. 1,964,988 shares of the stock were exchanged, compared to its average volume of 1,591,550. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of 26.83 and a beta of 1.23. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. Aurinia Pharmaceuticals Inc has a 1-year low of $5.29 and a 1-year high of $11.80. The stock has a fifty day moving average of $8.56 and a two-hundred day moving average of $8.21.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. The firm had revenue of $70.01 million during the quarter, compared to the consensus estimate of $64.27 million. Research analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AUPH. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Royal Bank Of Canada boosted their price objective on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a report on Friday, August 1st.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang acquired 200,000 shares of the business's stock in a transaction on Tuesday, August 5th. The shares were acquired at an average price of $11.68 per share, with a total value of $2,336,000.00. Following the completion of the transaction, the director owned 11,329,500 shares in the company, valued at approximately $132,328,560. This trade represents a 1.80% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders purchased 1,300,000 shares of company stock worth $13,590,000 over the last three months. Company insiders own 12.20% of the company's stock.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.